I am a
Home I AM A Search Login

Papers of the Week

Papers: 12 Mar 2022 - 18 Mar 2022

Pharmacology/Drug Development

2022 Mar 15

Pain Manag

Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study.


Martin SJ, McAnally HB, Okediji P, Rogosnitzky M
Pain Manag. 2022 Mar 15.
PMID: 35289682.


To evaluate the use of low-dose naltrexone (LDN) as a broad-spectrum analgesic. Retrospective cohort study from a single pain management practice using data from 2014 to 2020. Thirty-six patients using LDN for ≥2 months were matched to 42 controls. Pain scores were assessed at initial visit and at most recent/final documented visit using a 10-point scale. Cases reported significantly greater pain reduction (-37.8%) than controls (-4.3%; p < 0.001). Whole sample multivariate modeling predicts 33% pain reduction with LDN, with number needed to treat (for 50% pain reduction) of 3.2. Patients with neuropathic pain appeared to benefit even more than those with 'nociceptive'/inflammatory pain. LDN is effective in a variety of chronic pain states, likely mediated by TLR-4 antagonism.